Table 3 Comparison of sources’ overlapping coverage of unique drug names, indication terms, and drug-indication relations before and after normalization

1.64

1.30

1.02

1.87

1.80

1.14

0.23

0.50

0.12

1.62

3.40

1.03

2.09

6.77

1.38

0.47

3.37

0.35

3.81

3.37

1.07

4.66

6.67

1.96

0.85

3.30

0.89

1.91

3.29

1.03

2.59

6.54

1.40

0.68

3.25

0.37

2.81

1.33

1.03

3.08

4.54

1.43

0.27

3.21

0.40

5.56

1.60

1.17

6.14

4.68

2.32

0.58

3.08

1.15

1.00

1.80

1.00

2.21

4.17

1.44

1.21

2.37

0.44

2.51

1.14

1.01

3.11

3.40

1.72

0.60

2.26

0.71

3.03

1.47

1.02

3.34

3.30

1.81

0.31

1.83

0.79

4.68

1.60

1.15

5.18

2.79

1.48

0.50

1.19

0.33

5.46

2.45

1.41

6.24

3.61

1.76

0.78

1.16

0.35

5.63

1.49

1.20

6.24

2.62

1.70

0.61

1.13

0.50

2.41

1.53

1.03

2.62

2.06

1.08

0.21

0.53

0.05